Theriva Biologics Stock Retained Earnings

TOVX Stock  USD 1.37  0.07  4.86%   
Theriva Biologics fundamentals help investors to digest information that contributes to Theriva Biologics' financial success or failures. It also enables traders to predict the movement of Theriva Stock. The fundamental analysis module provides a way to measure Theriva Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Theriva Biologics stock.
Last ReportedProjected for Next Year
Retained Earnings-278.4 M-264.5 M
Retained Earnings is likely to rise to about (264.5 M) in 2025.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Theriva Biologics Company Retained Earnings Analysis

Theriva Biologics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.

Retained Earnings

 = 

Beginning RE + Income

-

Dividends

More About Retained Earnings | All Equity Analysis

Current Theriva Biologics Retained Earnings

    
  (309.32 M)  
Most of Theriva Biologics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Theriva Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Theriva Retained Earnings Driver Correlations

Understanding the fundamental principles of building solid financial models for Theriva Biologics is extremely important. It helps to project a fair market value of Theriva Stock properly, considering its historical fundamentals such as Retained Earnings. Since Theriva Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Theriva Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Theriva Biologics' interrelated accounts and indicators.
0.95-0.73-0.77-0.020.530.870.620.59-0.360.46-0.330.770.930.89-0.930.570.89-0.6-0.50.57-0.5
0.95-0.77-0.7-0.190.230.870.490.51-0.30.38-0.350.670.90.89-0.920.620.86-0.51-0.420.48-0.42
-0.73-0.770.54-0.01-0.2-0.960.040.040.31-0.290.05-0.15-0.66-0.790.61-0.84-0.58-0.03-0.040.03-0.04
-0.77-0.70.54-0.14-0.54-0.64-0.58-0.50.51-0.570.51-0.61-0.57-0.510.74-0.11-0.690.510.33-0.460.33
-0.02-0.19-0.01-0.140.50.08-0.09-0.16-0.230.20.0-0.15-0.24-0.250.24-0.18-0.190.130.06-0.110.06
0.530.23-0.2-0.540.50.350.550.43-0.330.41-0.120.550.40.32-0.390.060.4-0.46-0.390.44-0.39
0.870.87-0.96-0.640.080.350.170.19-0.370.4-0.150.350.790.85-0.740.790.7-0.2-0.190.19-0.19
0.620.490.04-0.58-0.090.550.170.83-0.250.39-0.540.950.540.38-0.65-0.180.64-0.82-0.60.73-0.6
0.590.510.04-0.5-0.160.430.190.83-0.20.38-0.390.870.650.4-0.69-0.070.63-0.99-0.790.92-0.79
-0.36-0.30.310.51-0.23-0.33-0.37-0.25-0.2-0.960.79-0.18-0.17-0.160.220.0-0.240.190.11-0.220.11
0.460.38-0.29-0.570.20.410.40.390.38-0.96-0.820.340.290.19-0.330.020.29-0.36-0.360.35-0.36
-0.33-0.350.050.510.0-0.12-0.15-0.54-0.390.79-0.82-0.42-0.13-0.040.270.27-0.270.360.27-0.330.27
0.770.67-0.15-0.61-0.150.550.350.950.87-0.180.34-0.420.740.59-0.810.060.79-0.87-0.690.81-0.69
0.930.9-0.66-0.57-0.240.40.790.540.65-0.170.29-0.130.740.94-0.940.680.89-0.65-0.530.61-0.53
0.890.89-0.79-0.51-0.250.320.850.380.4-0.160.19-0.040.590.94-0.880.790.89-0.41-0.250.4-0.25
-0.93-0.920.610.740.24-0.39-0.74-0.65-0.690.22-0.330.27-0.81-0.94-0.88-0.49-0.930.680.51-0.630.51
0.570.62-0.84-0.11-0.180.060.79-0.18-0.070.00.020.270.060.680.79-0.490.440.07-0.04-0.06-0.04
0.890.86-0.58-0.69-0.190.40.70.640.63-0.240.29-0.270.790.890.89-0.930.44-0.66-0.350.66-0.35
-0.6-0.51-0.030.510.13-0.46-0.2-0.82-0.990.19-0.360.36-0.87-0.65-0.410.680.07-0.660.78-0.950.78
-0.5-0.42-0.040.330.06-0.39-0.19-0.6-0.790.11-0.360.27-0.69-0.53-0.250.51-0.04-0.350.78-0.761.0
0.570.480.03-0.46-0.110.440.190.730.92-0.220.35-0.330.810.610.4-0.63-0.060.66-0.95-0.76-0.76
-0.5-0.42-0.040.330.06-0.39-0.19-0.6-0.790.11-0.360.27-0.69-0.53-0.250.51-0.04-0.350.781.0-0.76
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
Competition

Based on the latest financial disclosure, Theriva Biologics has a Retained Earnings of (309.32 Million). This is 133.21% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is 103.32% higher than that of the company.

Theriva Retained Earnings Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Theriva Biologics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Theriva Biologics could also be used in its relative valuation, which is a method of valuing Theriva Biologics by comparing valuation metrics of similar companies.
Theriva Biologics is currently under evaluation in retained earnings category among its peers.

Theriva Fundamentals

About Theriva Biologics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Theriva Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theriva Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theriva Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Theriva Stock Analysis

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.